Blockchain Registration Transaction Record

NanoViricides Advances Measles Treatment with NV-387 Animal Trial

NanoViricides, Inc. initiates animal trial for NV-387, targeting Measles amid rising global cases. A breakthrough in antiviral therapy could be on the horizon.

The resurgence of Measles, fueled by vaccine failures and declining immunization rates, poses a significant public health challenge worldwide. NanoViricides' development of NV-387 as a potential therapeutic offers hope in combating this preventable disease, especially in regions where vaccination coverage is inadequate. The success of NV-387 could revolutionize the treatment of Measles and other viral infections, providing a much-needed alternative to traditional vaccines and addressing a critical gap in global health security.